WO2006025304A1 - 動脈硬化検知用mri造影剤 - Google Patents
動脈硬化検知用mri造影剤 Download PDFInfo
- Publication number
- WO2006025304A1 WO2006025304A1 PCT/JP2005/015631 JP2005015631W WO2006025304A1 WO 2006025304 A1 WO2006025304 A1 WO 2006025304A1 JP 2005015631 W JP2005015631 W JP 2005015631W WO 2006025304 A1 WO2006025304 A1 WO 2006025304A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- contrast agent
- mri
- group
- mri contrast
- chemical
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/45—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
- C07C309/49—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
- C07C309/50—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms having at least one of the sulfo groups bound to a carbon atom of a six-membered aromatic ring being part of a condensed ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/20—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations containing free radicals, e.g. trityl radical for overhauser
Definitions
- the present invention belongs to the technical field of preparations for in vivo tests, and particularly relates to a contrast agent useful for detecting an arteriosclerotic site using MRI.
- Atherosclerosis (symptoms) has a great impact on the brain, heart, and kidney, which are indispensable for life support activities, and its diagnosis is extremely important.
- Atheromatous plaque that narrows the lumen of arteries by building up atheromatous plaque (atherosclerotic plaque) by accumulating atheromatous substances such as cholesterol in the intima of arteries Hardening
- atheromatous plaque that narrows the lumen of arteries by building up atheromatous plaque (atherosclerotic plaque) by accumulating atheromatous substances such as cholesterol in the intima of arteries Hardening
- Arterial stiffness resulting from arterial thickening and lumen constriction due to changes due to hypertension and (3) Menkelberg type in which calcium accumulates in the media of the artery, causing ring-shaped calcification (Medium)
- Hardening is classified into three types, among which the most important clinicopathologically is the basis of serious diseases such as cerebral infarction, aortic aneurysm, ischemic heart disease, limb gangrene It is atherosclerosis.
- MRI Magnetic Resonance Imaging: Magnetic Resonance Imaging
- MRI Magnetic Resonance Imaging
- a detailed examination is performed using means such as ultrasonic examination, CT examination, blood flow scintigram for injecting an isotope, and endoscopic observation for inserting a catheter.
- diagnosis using MRI is useful as a non-invasive test method that does not cause pain to the patient, but conventional MRI examinations are generally used for overall arterial stenosis, occlusion, or dilation.
- arteriosclerosis lesion site This is to check the degree, not to directly detect the arteriosclerosis site (arteriosclerosis lesion site). If it is possible to detect the arteriosclerosis site, in particular, the site where atherosclerosis has occurred, it is considered that it can contribute to early diagnosis and early treatment of various diseases derived from arteriosclerosis. I can hardly find it.
- Non-Patent Document 1 Circulation. June 15, 2004: 2890-2896
- An object of the present invention is to provide an MRI contrast agent for detecting arterial stiffness that can directly detect and image an arteriosclerosis site.
- an MR comprising an atom and / or molecule having an unpaired electron
- an MRI contrast agent for detecting arteriosclerosis characterized in that a detection unit that selectively recognizes an arteriosclerosis site and couples it to the contrast unit that increases or decreases the I signal is coupled.
- MRI contrast agent detection unit of the present invention include those containing a chemical structure represented by the following general formula (I), but are not limited thereto.
- R 1 At least one of R 8 , R 9 , R 10 and R 11 may independently be a sulfonic acid group, a hydroxyl group, or an amino group, and R 1 , RR 3 and R 4 At least one of the above functional groups, which may be an alkyl group or an alkoxy group having carbon atoms:! R 6
- R 7 , R 8 , R 1Q and R 11 represent a hydrogen atom
- X if present, represents a phenyl group, or a phenyl group substituted at least at one place with an alkyl group or alkoxy group having 1 to 3 carbon atoms. Represent.
- an arteriosclerotic site itself including atherosclerosis made of atherosclerotic plaques can be directly detected and imaged.
- MRI contrast agents can perform MRI measurements under normal MRI conditions and do not require special imaging processing.
- the MRI contrast agent of the present invention can be easily prepared using a known synthetic reaction, and is used as a contrast agent in a relatively small amount, so its cost is low.
- FIG. 1 shows a reaction scheme for synthesizing an example of the MRI contrast agent of the present invention.
- FIG. 2 shows the results of MRI imaging when the MRI contrast medium of the present invention is administered to a 12-month-old ApoE knockout mouse.
- FIG. 3 shows the results of MRI imaging when Gd-DTPA was administered to 12-month-old ApoE knockout mice.
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 may be independently a sulfonic acid group (one SO 2 H), a hydroxyl group (10 H), or an amino group (one NH 3). That is! ⁇ ⁇ 11
- All are hydrogen atoms (unsubstituted) or at least one is a sulfonic acid group, a hydroxyl group or an amino group, and!
- ⁇ to 11 are a sulfonic acid group, a hydroxynole group or an amino group
- these two or more functional groups may be the same or different from each other.
- at least one of R ⁇ R 11 is a sulfonic acid group.
- R 1 R 2 , R 3 and R 4 may be an alkyl group or an alkoxy group having 1 to 3 carbon atoms, and a methyl group is particularly preferable.
- X may not be present.
- —NH is directly bonded to the benzene ring represented by formula (I).
- X if present, represents a phenyl group or a phenyl group substituted with at least one alkyl group or alkoxy group having 1 to 3 carbon atoms (preferably a methyl group).
- the MRI contrast agent contrast unit of the present invention is not particularly limited as long as it includes atoms and / or molecules having unpaired electrons and increases or decreases the MRI signal. In other words, it is based on actions such as shortening the proton relaxation time (T, T) in MRI.
- the MRI contrast agent of the present invention can be used as a contrast unit.
- chelate complexes of paramagnetic metal ions Gd Dy 3 + , Eu + , Fe 3+ , Mn 2+ etc.
- nitroxide radical molecules such as piperidine derivatives and pyrrolidine derivatives
- magnetite Fe 2 O 3
- the contrast unit is composed of a DTPA (diethylenetriaminepentaacetic acid) complex of G d (III), and the detection unit is represented by the chemical formula ( ⁇ ) above.
- DTPA diethylenetriaminepentaacetic acid
- the structural formula force include those represented by the following formula (VII), but of course not limited thereto.
- the MRI contrast agent of the present invention can be easily synthesized by devising a known reaction.
- a metal complex such as a gadolinium chelate complex
- an amino compound corresponding to a part of the detection unit represented by the formula (I) is generally Boc-converted (t-butoxycarbonyl).
- Boc group is removed, the remaining part of the detection unit represented by formula (I) is bound by a diazo coupling reaction, and then complexed with the metal.
- MRI contrast medium can be obtained (see Example 1 below).
- the detection unit selectively recognizes the arteriosclerotic site and binds to the site, and the contrast unit converts this to the MRI signal ( Capable of imaging as a fern.
- Example 1 is given below to illustrate the features of the present invention more specifically, but the present invention is not limited to these examples.
- Example 1
- the MRI contrast agent of the present invention represented by the aforementioned formula (VII) was synthesized.
- DMB— DTPA 65 mg (62.3 ⁇ mol), 35% HC1: 16.5 ⁇ 1 (187 ⁇ mol) mixed in 1 ml of water, added with NaN ⁇ : 4.5 mg (65.2 x mol), and stirred for 30 minutes As a result, diazonium salting was performed. This was added dropwise to 1 ml of an aqueous solution containing 1-amino 1-naphthol-1,4-disulfonic acid mono- sodium salt 21.203 ⁇ 4 (62.2 0101) and Na CO 26.4 mg (249 ⁇ mol) on an ice bath. Zo coupling was performed. After completion of the reaction, 35% HC1 was added dropwise to the reaction solution, and this was recovered to obtain the desired product. Yield: 42.5 mg.
- the contrast medium (EB_DTPA_Gd) synthesized in Example 1 was evaluated for contrast using ApoE knockout mice.
- a similar evaluation experiment was performed for Gd_DTPA, which is a well-known contrast agent as a control.
- the ApoE knockout mouse (commercially available from Kudo Co., Ltd.) is a model mouse for arteriosclerosis. Atherosclerosis progresses with age and causes cardiovascular disease.
- ApoE knockout mice (6 months or 12 months old, body weight 32 g to 36 g) were fixed to probes for in vitro MRI, and MRI images before administration were imaged. Thereafter, physiological saline solution of EB-DTPA-Gd or Gd-DTPA was administered via the tail vein, and imaging was started immediately after.
- the contrast medium dose was 160 / i mol / kg (260-290 / 1 as 20 mM solution for EB-DTPA-Gd and 100 uL as 50 mM solution for Gd-DTPA). Imaging conditions are as follows: imaging time (9m36s), TR (500msec), Te (25msec), T1 weighted by spin echo method.
- FIG. 2 is a photograph of a cross section taken in the longitudinal direction of the body of the mouse. To facilitate understanding, the position of the diaphragm before administration and the position of the signal of the ascending aorta after administration are shown by hand. In the 6-month-old mice, there were scattered spots where the signal increased. This point coincided with the position of the unstable plaque.
- Gd_DTP A which is a general contrast agent, did not show any increase in the blood vessel signal after the same administration (see Fig. 3).
- contrast enhancement EB-DTPA-Gd according to the present invention was administered to normal mice and contrast evaluation was attempted under the same conditions, no change in contrast was observed.
- the contrast agent of the present invention has the ability to detect unstable plaques at the site of arteriosclerotic lesions.
- the MRI contrast medium of the present invention can directly detect the site of arteriosclerosis represented by atherosclerosis, it is extremely useful for early diagnosis and early treatment of various diseases caused by arteriosclerosis. is there.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006532657A JPWO2006025304A1 (ja) | 2004-08-30 | 2005-08-29 | 動脈硬化検知用mri造影剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004249507 | 2004-08-30 | ||
JP2004-249507 | 2004-08-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006025304A1 true WO2006025304A1 (ja) | 2006-03-09 |
Family
ID=35999958
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/015631 WO2006025304A1 (ja) | 2004-08-30 | 2005-08-29 | 動脈硬化検知用mri造影剤 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2006025304A1 (ja) |
WO (1) | WO2006025304A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012014994A1 (ja) * | 2010-07-30 | 2012-02-02 | ダイトーケミックス株式会社 | ナフタレン誘導体 |
WO2019070236A1 (en) * | 2017-10-03 | 2019-04-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIATION THERAPY AND IMAGING AGENTS |
US10696631B2 (en) | 2016-05-09 | 2020-06-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents |
US10709790B2 (en) | 2015-06-22 | 2020-07-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chemical conjugates of Evans Blue derivatives and their use in the production of long-acting therapeutics |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000050042A1 (en) * | 1999-02-22 | 2000-08-31 | Apologic, Incorporated | Methods for the treatment of apolipoprotein e related diseases |
WO2004075925A1 (ja) * | 2003-02-27 | 2004-09-10 | Kyushu Tlo Company Limited | Mri用造影剤 |
-
2005
- 2005-08-29 JP JP2006532657A patent/JPWO2006025304A1/ja active Pending
- 2005-08-29 WO PCT/JP2005/015631 patent/WO2006025304A1/ja active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000050042A1 (en) * | 1999-02-22 | 2000-08-31 | Apologic, Incorporated | Methods for the treatment of apolipoprotein e related diseases |
WO2004075925A1 (ja) * | 2003-02-27 | 2004-09-10 | Kyushu Tlo Company Limited | Mri用造影剤 |
Non-Patent Citations (5)
Title |
---|
IKUTA K. ET AL: "Kekkan Naihi Shogai Bui o Ninshiki suru Shinki Kinoka Zoeizai no Kaihatsu", THE CHEMICAL SOCIETY OF JAPAN, KOEN YOKOSHU, vol. 83, no. 2, 2003, pages 972 1-G3-46, XP002999515 * |
URASAKI T. ET AL: "Kekkan Naihi Shogai o Ninshiki suru Shinki MRI Zoeizai no Gosei to Hyoka", THE JAPAN SOCIETY FOR ANALYTICAL CHEMISTRY NENKAI KOEN YOSHISHU, vol. 52, 18 August 2004 (2004-08-18), pages 141, J1018, XP002999517 * |
YAMAMOTO T. ET AL: "First functionalized MRI contrast agen recognizing vascular lesions", ANAL.SCI., vol. 20, no. 1, January 2004 (2004-01-01), pages 5 - 7, XP002979741 * |
YAMAMOTO T. ET AL: "In vivo MR detection of vascular endothelial injury using a new class of MRI contrast agent", BIOORG.MED.CHEM.LETT., vol. 14, no. 11, 2004, pages 2787 - 2790, XP004841288 * |
YAMAMOTO T. ET AL: "Kekkan Naihi Shogai Sensing o Shiko shita Shinki MRI Zoeizai", THE JAPAN SOCIETY FOR ANALYTICAL CHEMISTRY NENKAI KOEN YOSHISHU, vol. 52, 2003, pages 141, IG23, XP002999516 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012014994A1 (ja) * | 2010-07-30 | 2012-02-02 | ダイトーケミックス株式会社 | ナフタレン誘導体 |
JP5828201B2 (ja) * | 2010-07-30 | 2015-12-02 | ダイトーケミックス株式会社 | ナフタレン誘導体 |
US9573887B2 (en) | 2010-07-30 | 2017-02-21 | Daito Chemix Corporation | Naphthalene derivative |
US10709790B2 (en) | 2015-06-22 | 2020-07-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chemical conjugates of Evans Blue derivatives and their use in the production of long-acting therapeutics |
US10696631B2 (en) | 2016-05-09 | 2020-06-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents |
WO2019070236A1 (en) * | 2017-10-03 | 2019-04-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIATION THERAPY AND IMAGING AGENTS |
CN111542518A (zh) * | 2017-10-03 | 2020-08-14 | 由卫生与公众服务部部长代表的美利坚合众国 | 埃文斯蓝衍生物的化学缀合物及其作为放射治疗剂和成像剂的用途 |
US10981866B2 (en) | 2017-10-03 | 2021-04-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chemical conjugates of Evans Blue derivatives and their use as radiotherapy and imaging agents |
CN111542518B (zh) * | 2017-10-03 | 2023-10-10 | 由卫生与公众服务部部长代表的美利坚合众国 | 埃文斯蓝衍生物的化学缀合物及其作为放射治疗剂和成像剂的用途 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2006025304A1 (ja) | 2008-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6542748B2 (ja) | 濃度非依存応答性を示すcestシステム | |
JP2003201258A (ja) | 多座結合を介した多量体画像化剤の標的化 | |
JP2894879B2 (ja) | 診断用造影剤 | |
JPS63502834A (ja) | 核磁気共鳴画像増強剤およびその使用 | |
CN102781909B (zh) | 作为显像剂的n-烷氧基酰胺共轭物 | |
EP3551614B1 (en) | Dimeric contrast agents | |
JPH06181890A (ja) | Mri造影剤 | |
CN114981279A (zh) | 新型钆基化合物、其制备方法及含有其的mri造影剂 | |
WO2006025304A1 (ja) | 動脈硬化検知用mri造影剤 | |
JP2006514664A (ja) | 三量体である大環状で置換されたベンゼン誘導体 | |
JP4569875B2 (ja) | Mri用造影剤 | |
NZ513907A (en) | Perfluoroalkylamide, the production thereof and the use thereof in diagnostics | |
CN110357828B (zh) | 一种核磁共振造影剂及其制备方法和用途 | |
CA2419259A1 (en) | Complexes containing perfluoroalkyl with polar radicals, method for the production and use thereof | |
JP2901787B2 (ja) | 核磁気共鳴造影剤 | |
TW200539894A (en) | Trimeric, macrocyclically substituted halo-benzene derivatives | |
MXPA04012950A (es) | Uso de metales complejos conteniendo perfluoroalquilo coo agente contrastante de la reproduccion optica en resonancia magnetica para la representacion trombo intravascular. | |
US6676928B2 (en) | Perfluoroalkyl-containing complexes with polar radicals, process for their production and their use | |
JP2012512844A (ja) | Mriイメージングのための高性能な造影剤 | |
KR100762359B1 (ko) | 신생혈관특이적 엠알 조영제 및 이의 제조방법 | |
CN110396122B (zh) | 一种核磁共振造影剂、制备方法及其用于肿瘤诊断中的用途 | |
US20040131546A1 (en) | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of intravascular thrombi | |
US20040022735A1 (en) | Enzyme activated contrast agents | |
KR20120107541A (ko) | 유리딘계 가돌리늄 착물 및 이를 포함하는 mri 조영제 | |
Wong et al. | Gadolinium complexes as MRI contrast agents for diagnosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006532657 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |